Details of Disease

General Information of Disease (ID: DISVCAQB)

• Disease Name: Dengue fever
• Disease Class: 1D2Z: Dengue fever
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISVCAQB: Dengue fever
• ICD Code:
  ICD-11: ICD-11: 1D2Z
  ICD-10: ICD-10: A97, A97.9
  ICD-9: ICD-9: 61
  Expand ICD-11: '1D2Z
  Expand ICD-10: 'A97; 'A97.9
  Expand ICD-9: 61
• Disease Identifiers:
  MONDO ID: MONDO_0005502
  MESH ID: D003715
  UMLS CUI: C0011311
  MedGen ID: 3721
  Orphanet ID: 99828
  SNOMED CT ID: 38362002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 11 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dengue fever vaccine	DMGN6RZ	Phase 3	NA	[1]
TAK-003	DMKVC5U	Phase 3	NA	[2]
ChimeriVax-Dengue	DMS2FU1	Phase 2	NA	[3]
Dengvaxia	DM48OPL	Phase 2	NA	[2]
DeNVax	DMZ0K56	Phase 2	NA	[4]
RDEN1delta30	DM3FCUP	Phase 2	NA	[5]
V181	DMSLVXA	Phase 2	Vaccine	[6]
Celgosivir	DMD1V7I	Phase 1/2	Small molecular drug	[7]
TDENV	DMR61GX	Phase 1/2	NA	[2]
HBV-001-D1	DM6DC1J	Phase 1	NA	[8]
V180	DMVEU3U	Phase 1	NA	[9]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
FX-107	DM7UJ1I	Preclinical	NA	[10]

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ASB-010	DM434OZ	Investigative	NA	[11]
AVI-6006	DMV4VK1	Investigative	NA	[11]
HydroVAX	DM069X6	Investigative	NA	[11]
Imino sugars	DMSINGH	Investigative	NA	[12]
RO-0534	DMQPXNC	Investigative	NA	[11]
WSS-45	DMWUPVB	Investigative	NA	[11]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Clinical pipeline report, company report or official report of Sanofi Pasteur.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT00730288) Study of ChimeriVax Dengue Tetravalent Vaccine in Adult Subjects. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT01511250) Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT01696422) Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT05507450) A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENVdelta30 [Live, Attenuated]) in Healthy Adults. U.S.National Institutes of Health.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003977)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015855)
• [9] ClinicalTrials.gov (NCT01477580) Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001). U.S. National Institutes of Health.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023709)
• [11] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).